title: Essential role of extracellular charged residues of the human CCK(1) receptor for interactions with SR 146131, SR 27897 and CCK-8S.
abstract: We hypothesized that charge-charge interactions may be important for the binding of the human cholecystokinin type 1 (CCK(1)) receptor-specific non-peptide full agonist SR 146131, (2-[4-(4-chloro-2, 5-dimethoxyphenyl)-5-(2-cyclohexyl-ethyl)-thiazol-2-ylcarbamoyl ]-5, 7-dimethyl-indol-1-yl-1-acetic acid), the competitive antagonist SR 27897, (1-[2-(4-(2-chlorophenyl)thiazol-2-yl) aminocarbonyl indoyl] acetic acid) and the natural octapeptide CCK-8S to the CCK(1) receptor. Alanine replacement studies of positively charged residues in the extracellular domains of the receptor showed that only the R336A mutation affected SR 146131 potency of mutated receptors transiently expressed in monkey kidney epithelial COS-7 cells. Two residues, Lys(115) and Lys(187), were implicated in SR 27897 binding. Only the replacement of Lys(115), Arg(197) and Arg(336) significantly affected CCK-8S binding or activity. These results clearly indicated the importance of certain charged residues, but not others, in SR 146131, SR 27897 and CCK-8S binding. Furthermore, although these molecules probably occupy different binding sites on the CCK(1) receptor, we show that a small non-peptide agonist, SR 146131, can stimulate the dual signaling pathways mediated by the CCK(1) receptor.
authors.affiliation: Sanofi-Synthelabo, Centre de Labège, Labège-Innopole Voie No. 1, B. P. 137, 31676, Labège, France. paul.gouldson@sanofi.com
authors.forename: P
authors.initials: P
authors.lastname: Gouldson
authors.forename: P
authors.initials: P
authors.lastname: Legoux
authors.forename: C
authors.initials: C
authors.lastname: Carillon
authors.forename: X
authors.initials: X
authors.lastname: Dumont
authors.forename: G
authors.initials: G
authors.lastname: Le Fur
authors.forename: P
authors.initials: P
authors.lastname: Ferrara
authors.forename: D
authors.initials: D
authors.lastname: Shire
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D019556:COS Cells; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007210:Indoleacetic Acids / Q000378:metabolism*; D007211:Indoles / Q000378:metabolism*; D007295:Inositol Phosphates / Q000378:metabolism; D008969:Molecular Sequence Data; D009154:Mutation; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000737:chemistry / Q000378:metabolism*; D012844:Sincalide / Q000031:analogs & derivatives* / Q000378:metabolism; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000378:metabolism*
chemical_list: C090019:8-sulfocholecystokinin octapeptide; D007210:Indoleacetic Acids; D007211:Indoles; D007295:Inositol Phosphates; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; C118846:SR 146131; D013844:Thiazoles; C080460:SR 27897; D012844:Sincalide